EGFR and non-small cell lung carcinoma: Thus, the CheckMate026 study compared nivolumab at a dose of 3 mg/kg Q2W versus platinum-based CT in patients with stage IV NSCLC with PD-L1 expression >5% in tumor cells and without EGFR- and ALK-activating mutations, but this time the results was negative.